Jun 26 2026
United States Court… 23-5311 Panel Decision

NORWICH PHARMACEUTICALS, INC v. ROBERT F. KENNEDY, JR

The United States Court of Appeals for the District of Columbia Circuit affirmed a district court ruling regarding the approval timeline for a generic drug application. The court held that a final judgment barring approval of a specific application number applies even if the applicant amends the application to remove infringing indications.

Jun 23 2026
4th Cir. 25-1158 Per Curiam

Vir2us, Inc. v. Sophos Inc.

The Fourth Circuit affirmed a district court ruling that Sophos products were not subject to royalty payments under a patent license agreement. The court held that sharing source code does not make a product a legal derivation of a containerized product when the shared code is unrelated to the product's primary function.

Jun 23 2026
Fed. Cir. 25-1427 Panel Decision

ENANTA PHARMACEUTICALS, INC v. PFIZER INC

The United States Court of Appeals for the Federal Circuit affirmed a district court ruling that invalidated Enanta Pharmaceuticals' patent claims. The court held that the patent could not claim priority from an earlier provisional application because the provisional did not adequately describe the specific chemical compound at issue.

Jun 23 2026
Fed. Cir. 25-1419 Panel Decision

PACT XPP Schweiz AG v. Intel Corporation

The United States Court of Appeals for the Federal Circuit affirmed a district court ruling that Intel Corporation did not infringe two patents held by PACT XPP Schweiz AG. The appellate court held that PACT failed to properly raise a capability-based infringement theory and that the district court correctly construed the patent claims based on the prosecution history.